Stockscreener 앱 받기
1.93
6.63%
0.12
시간 외 거래:
1.98
0.05
+2.59%
전일 마감가:
$1.81
열려 있는:
$1.93
하루 거래량:
59,305
Relative Volume:
1.21
시가총액:
$17.93M
수익:
-
순이익/손실:
$-45.57M
주가수익비율:
-0.3063
EPS:
-6.3
순현금흐름:
$-38.56M
1주 성능:
+6.63%
1개월 성능:
+16.62%
6개월 성능:
-33.90%
1년 성능:
-26.89%
1일 변동 폭
$1.80
$2.00
1주일 범위
$1.7117
$2.00
52주 변동 폭
$1.00
$5.01
Sab Biotherapeutics Inc Stock (SABS) Company Profile
명칭
Sab Biotherapeutics Inc
전화
305-845-2813
주소
777 W 41ST ST, MIAMI BEACH
SABS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
1.93 | 16.82M | 0 | -45.57M | -38.56M | -6.30 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-10-09 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-05 | 개시 | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital - Defense World
Analysts Offer Predictions for SABS Q2 Earnings - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Monday - Defense World
HC Wainwright Initiates Coverage on SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Brookline Capital Management Comments on SABS Q2 Earnings - Defense World
SABS Maintains Buy Rating by Chardan Capital with $20 Target | S - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
SAB Biotherapeutics (SABS) Receives New "Buy" Rating from Analys - GuruFocus
SAB Biotherapeutics (SABS) Receives Buy Rating and $10 Target fr - GuruFocus
Head to Head Analysis: SAB Biotherapeutics (SABS) and Its Peers - Defense World
SAB BIO (SABS) Reports Cash Decrease as Progress in T1D Therapy Advances | SABS Stock News - GuruFocus
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewswire
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Shares Purchased by Geode Capital Management LLC - Defense World
Financial Review: SAB Biotherapeutics (SABS) & The Competition - Defense World
Head-To-Head Review: SAB Biotherapeutics (SABS) versus Its Peers - Defense World
SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast - Defense World
SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
FY2025 Earnings Forecast for SABS Issued By Chardan Capital - Defense World
HC Wainwright Brokers Boost Earnings Estimates for SABS - Defense World
SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - The AM Reporter
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan - TipRanks
Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating - TipRanks
SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire
SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials - Stock Titan
SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 - TipRanks
SAB Biotherapeutics, Inc. SEC 10-K Report - TradingView
Financial Contrast: SAB Biotherapeutics (NASDAQ:SABS) versus Kiromic BioPharma (NASDAQ:KRBP) - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36 - MSN
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 6.7% – Here’s Why - Defense World
SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142 - News-Medical.Net
Q1 Earnings Estimate for SABS Issued By HC Wainwright - Defense World
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
Diabetes Treatment Pioneer SAB BIO Sets Stage for Major Investor Presentations - StockTitan
United States shares higher at close of trade; Dow Jones Industrial Average up 0.31% - Investing.com India
Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
SAB Biotherapeutics To Advance SAB-142 Into Phase 2b Trials After Positive Phase 1 Results - Nasdaq
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Marketscreener.com
Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences plunged by 92.99% in early trading - Business Upturn
3 Promising US Penny Stocks With At Least $20M Market Cap - simplywall.st
SAB Biotherapeutics (SABS) Stock Price, News & Analysis - MarketBeat
SAB BIO Announces R&D Webinar Event to Review Phase 1 - GlobeNewswire
SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar - StockTitan
10 Best Diabetes Stocks To Buy Under $10 - Insider Monkey
Sab Biotherapeutics Inc (SABS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):